← 返回

瘤内 NKp46⁺ NK 细胞与 T 细胞及 MHC-I⁺ 细胞在空间上远离,在软组织肉瘤中具有预后意义

英文原题:Intratumoral NKp46(+) natural killer cells are spatially distanced from T and MHC-I(+) cells with prognostic implications in soft tissue sarcoma.

查看英文原题

Intratumoral NKp46(+) natural killer cells are spatially distanced from T and MHC-I(+) cells with prognostic implications in soft tissue sarcoma.

PubMed 2023/07/21(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

肿瘤内 NK 细胞在 STS 中具有预后意义,且与 T 细胞相比更靠近 MHC-I-细胞。尽管 NK 细胞和 T 细胞均与 STS 生存改善相关,但它们在 TME 中基于 MHC-I 表达状态的不同分布可作为改善免疫治疗选择的生物标志物。

研究思路结论见上方概要

软组织肉瘤(STS)是一种罕见、异质性强的恶性肿瘤,对新免疫疗法的需求尚未得到满足。TIL(肿瘤浸润淋巴细胞)(TILs)与STS患者的良好预后相关,但自然杀伤(NK)细胞的作用以及TILs与表达MHC-I细胞的空间关系尚缺乏详细表征。

我们使用存档标本和前瞻性收集的标本,通过免疫组织化学(IHC)、流式细胞术和免疫荧光(IF)评估了肿瘤内NK细胞。我们通过多重IF评估了NK细胞和T细胞的空间定位,分析了MHC-I表达状态对NK细胞和T细胞聚集的影响。

肿瘤内NKp46和CD56 dim表达均与总生存期显著改善相关(P=0.05),而CD56bright NK细胞浸润较高则预示预后较差(P=0.05)。肿瘤内NK细胞的存在与CD3 + T细胞呈反比。空间分析显示,NK细胞优先聚集在其他NK细胞附近,而CD3 + T和CD8 + T细胞在该范围内分布稀疏(P<0.0001)。此外,与NK细胞相比,CD3 + T和CD8 + T细胞与MHC-I +细胞的共定位显著更多(P<0.0001)。新辅助放疗后,CD8聚集增加,而新辅助化疗后,TIL聚集总体降低。

展开英文摘要原文

Both intratumoral NKp46 and CD56 dim expression were associated with significantly improved overall survival (P=0.05), while higher infiltrates of CD56bright NK cells predicted a worse prognosis (P=0.05). The presence of intratumoral NK cells was inversely proportional to CD3 + T cells. Spatial analyses showed NK cells preferentially clustering close to other NK cells with sparse CD3 + T and CD8 + T cells in range (P<0.0001). Additionally, CD3 + T and CD8 + T cells showed significantly greater co-localization with MHC-I + cells, compared to NK cells (P<0.0001). After neoadjuvant radiotherapy, there was greater CD8 clustering, while after neoadjuvant chemotherapy, there was overall lower TIL clustering.

Intratumoral NK cells are prognostic in STS and localize closer to MHC-I- cells than T cells. Although both NK and T cells are associated with improved survival in STS, their differential distribution in the TME based on MHC-I expression status may serve as a biomarker for improved immunotherapy treatment selection.

论文信息

作者
Cruz SM、Sholevar CJ、Judge SJ、Darrow MA、Iranpur KR、Farley LE、Lammers M、Razmara AM
单位
Division of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, CA, United States.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Frontiers in immunology2023
原文标识
PubMed 37545516 · DOI 10.3389/fimmu.2023.1230534